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Abstract 
Background: Research has implicated that cannabis 
has an aetiological role in psychosis, and thus one can 
hypothesize that the onset of psychosis in patients who use 
cannabis occurs earlier in life than those who do not use 
cannabis 
Aim: The aim of this study is to assess the possible 
influence of cannabis on the age of onset of patients with 
first episode of psychotic illness admitted to a psychiatric 
unit in the Maltese Islands. 
Methods and sample: This study is a one year 
prospective study that includes all ICD-10 first episode 
psychosis patients admitted to a psychiatric hospital in the 
Maltese Islands. Age of admission to hospital was used as 
proxy for age of onset of psychosis. Use of cannabis prior 
to admission was ascertained by urine testing.  
Results: The mean age of admission to hospital for 
first onset psychosis for patients whose urine was 
positive to cannabis was 24.63 years old, and for 
patients whose urine was negative to cannabis was 
44.63 years old. This difference was statistically 
significant, using the Mann Whitney-U test p=0.001. 
Conclusion: The results indicate that cannabis use 
can precipitate an earlier onset of psychotic illness. 
Considering the widespread use of cannabis, and that 
earlier age of onset of psychosis is associated with 
worse prognosis, this issue is of public health concern. 
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Introduction 
Malta is an archipelago in the Mediterranean Sea, 
with a population of approximately half a million 
people. There are three National Health Service units 
that offer treatment for psychiatric patients. The 
largest is Mount Carmel Hospital, with around 600 
beds. Smaller units exist within two general hospitals: 
Mater Dei Hospital (main island) and in Gozo General 
Hospital (sister island Gozo). There is also a private 
hospital that occasionally admits patients with mental 
illness as well. 
Several case-control studies have shown that 
patients with schizophrenia are more likely to use 
cannabis than other psychiatric patients or normal 
controls.
1-4
 In 1987 Andreason et al.
5
 published a 
seminal paper of a follow-up study on a cohort of 
45,570 Swedish conscripts. In this cohort the relative 
risk for schizophrenia among high consumers of 
cannabis was six times more than in non-users of 
cannabis. Similar results were replicated in other 
follow-up studies.
6-9
 Thus one can conclude that it is 
very possible that cannabis can have an aetiological 
role in the development of schizophrenia.  
Due to this aetiological role, one can thus 
hypothesize that cannabis use can hasten the onset of 
psychotic illness and schizophrenia Four studies 
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conducted on patients with first episode of psychosis 
concluded that patients with psychosis who abuse cannabis 
have an earlier age of onset of illness compared to those 
who do not.
10-12
 Sungrayes et al.
13
 conducted a study on 
116 patients with first episode psychosis and subsequent 
diagnosis of schizophrenia (after a 12-month follow-up). 
Their findings showed that cannabis use was significantly 
associated with a decrease in age of first antipsychotic 
treatment, and that this correlated with frequency of 
cannabis use.  
Malta is a small country and thus it lends itself well to 
epidemiological studies that are based on the whole 
population. This research project is part of a larger study 
which involved calculating the incidence of psychosis of 
patients requiring admission to hospital on the Maltese 
Islands reported to be 26.0 per 100,000,  (95% CI: 25.9-
26.1).
14 
 We chose the Maltese Archipelago to test if the 
findings from studies reported elsewhere (that show that 
cannabis is associated with an earlier age of onset of 
psychosis) could be replicated in a study based on the 
whole population of a country.  
 
 
Methods 
Sample 
The study design used was a prospective cross-sectional 
study. The inclusion criteria for this study were all patients 
with a first episode of psychosis admitted to a psychiatric 
ward at any of the three government hospitals over one 
year. In Malta there is only one non-government hospital 
that admits patients with mental illness. Admissions for 
psychosis in this unit are very rare, and during the year of 
study there were no admissions of patients that fulfilled the 
inclusion criteria of the study. Participations included 
persons of all age, sex and ethnical background that were 
permanently resident in Malta. Tourists and irregular 
immigrants not living in the community were excluded 
from this study. 
 
Clinical assessment of the patient sample 
As part of the formal admission assessment the senior 
doctor established if this person suffered from a psychosis. 
After the patient was seen by the consultant psychiatrist 
and multidisciplinary team (MDT) the diagnosis was 
confirmed or dismissed. Only people with a diagnosis of 
psychosis by the MDT were included in the study. 
 
Age of onset of psychosis 
Age of admission to hospital was used as proxy for age 
of onset of psychosis.   
 
Assessment of cannabis use 
Use or otherwise of cannabis by the patients prior to the 
admission was ascertained by means of urine testing 
within the first few days of admission. 
 
Data protection 
All patients were invited to participate in the study, 
and were free to decline. Informed consent was given. 
They were informed that all data collected would be 
anonymous and confidential and that this study would 
not negatively or positively effect the treatment they 
received in hospital. 
This study was approved by the relevant hospital 
authorities. 
 
Statistics 
All data was imputed into Microsoft Excel and 
analysed using SPSS. Statistical difference looking at 
age of onset of psychosis in the two groups (those 
testing positive for cannabis and those testing negative 
for cannabis), was first analysed using parametric tests 
for continuous data (2 sample t-test). To increase the 
robustness of the statistical analysis a non-parametric 
test (Mann-Whitney U test) was used. This backed the 
statistical analysis of the 2 sample t-tests and also 
ensured that our sample was normally distributed - 
hence reducing any bias that could arise from having 
extreme outliers of age in the data. 
 
Results 
During the year of study there were 100 patients 
(males=55, females=45) with first episode of 
psychosis who were permanently resident in Malta and 
were admitted in one of all the in-patient psychiatric 
units of the Government Hospitals.  
All patients were asked to provide urine for 
analysis to ascertain the use or not of cannabis prior to 
the admission. 83 patients (males=39, females=36), 
accepted to have their urine analysed. Patients who 
refused urine testing were 10 males and 7 females. The 
mean age of the patients accepting urine testing was 42 
years (CI=38.8 - 44.0), and the mean age of patients 
refusing urine testing was 29 years. This difference 
was statistically significant, Man Whitney p=0.047. 
The difference in sex between the patients who refused 
and did not refuse urine testing was not statistically 
different. 
Eight patients (9.6%) tested positive for cannabis, 
by urine analysis, the mean age was 24.63 years (95% 
CI 20.1 – 29.3), and the mean age of admission of 
patients who resulted negative for cannabis in urine 
testing was 44.63 years. The difference was 
statistically significant, Mann Whitney p=0.001. 
The difference in sex distribution within the group 
of patients who were positive to cannabis in urine 
testing was not statistically different from that of 
patients who where negative to cannabis in urine 
testing; Fisher’s exact test, p 2 sided=0.279, p 1 
sided=0.194. 
  
 
Original Article 
 
 
 
 
Malta Medical Journal    Volume 24 Issue 03 2012                                                                                                              19 
 
 
 
Discussion 
This study was able to reproduce the result from 
previous studies carried out in other countries, that 
reported an association between cannabis use and earlier 
age of onset of psychosis. 
There can be various reasons for this association. The 
association could be coincidental or a result of 
confounding variables which were not accounted for in 
this study. Cannabis is used more in the younger 
generations. Therefore, there is a greater chance that 
patients who start suffering from psychosis at an earlier 
age, have also been using cannabis, than those who start 
suffering from psychosis at an older age. Another reason 
could be because of trends in substance misuse, where by 
males tend to misuse illicit substances more than females. 
Males also tend to have an earlier age of onset of psychotic 
illness than there counterparts in general. The fact that in 
this study the difference in sex distribution within the 
group of patients who tested positive for cannabis in urine 
was not statistically different from that of patients who 
where negative for cannabis in urine testing, indicates that 
the association found in this study between cannabis use 
and earlier age of onset of psychosis could not be due to 
this bias. 
It is also possible that the association between cannabis 
use and earlier age of onset of psychosis is because 
cannabis use precipitates psychosis in vulnerable 
individuals or that it could be the sole predisposing factor 
for psychotic illness in certain individuals. The fact that 
cannabis use can precipitate psychotic illness in vulnerable 
individuals is supported by the knowledge that cannabis as 
a substance can precipitate psychotic like symptoms in 
individuals who misuse this substance.
15-16
 Furthermore, 
epidemiological studies have reported that had individuals 
not misused cannabis (prior to developing a psychotic 
illness) they would have never developed a psychotic 
illness in their lifetime.
9, 17
 
All the causes discussed above are not mutually 
exclusive, and it is possible that the reason for the 
association between cannabis and age of onset of 
psychosis is a combination of the above factors. 
 
Validity and limitations  
One of the main strengths of this study is that it 
included admissions for a whole population of a country 
(there were no admissions for psychosis in Malta’s private 
hospital over the period of study). The authors are aware 
that there may have been some other patients who suffered 
from cannabis induced psychosis that were treated within 
the private sector, but instead of being admitted to hospital 
were managed using home treatment. Further discussion 
was carried out with consultants working in this area of 
speciality in Malta, and we were told that home treatment 
could have been used in a few cases if any, during the time 
period when the study was carried out. Due to this 
limitation this authors suggest that the data is reported 
with care. 
Since urine analysis was used to assess cannabis 
use by the subjects, the information about use of 
cannabis is very accurate and not subject to any bias. 
Future research could include the use of hair analysis, 
which would provide a better idea of the drug use 
patterns.  
It is very difficult to ascertain the exact time of the 
onset of psychosis. Thus we decided to use a proxy 
measure for onset of psychosis, which is the age of 
hospitalization for age of onset of psychosis. This can 
create a bias towards patients with insidious onset 
having their illness reported as starting at a later age 
than those with acute onset. This is because patients 
with acute onset of psychosis generally are admitted 
closer to the onset of their psychosis than those with a 
more insidious onset. 
Seventeen out of the 100 patients who fulfilled the 
inclusion criteria for the study refused to have their 
urine tested for use of cannabis. Those had a 
statistically significant younger age than those who did 
not refuse. There can be many reasons why patients 
refused to have their urine tested. Clinical experience 
in Malta shows that since in Malta smoking cannabis 
is illegal, patients who use cannabis are extremely 
reluctant to divulge this information. In fact it is 
common clinical practice to suspect that those who 
refuse to provide urine samples have a higher 
probability of having used illicit drugs prior to their 
admission. So it is likely that a significant number of 
those who refused to have their urine tested in the 
study could have been tested positive for cannabis. 
Considering that those who refused urine testing were 
younger than those who agreed to have their urine 
tested, the bias that their refusal to participate in the 
study might have caused is against, not in favour of the 
hypothesis of the study that cannabis use results in an 
earlier age of onset of psychosis.  
Data was solely collected from medical files 
without actually interviewing the respective MDT or 
patient’s themselves. Gathering more information or 
using a standardised instrument may have helped 
further to answer the research question. It could have 
also helped to shed more light on possible 
confounding variables which may also affect age of 
onset. 
 
Clinical implications 
Studies report that the prevalence of cannabis use 
amongst young people is on the increase. This study 
concludes that there is an association between 
cannabis use and an earlier age of onset of psychosis. 
Early age of onset of psychosis is associated with 
worse prognosis. Thus: from a research perspective it 
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is very important that the nature of the association between 
cannabis use and earlier age of onset of psychosis is 
studied more in depth. From a service provision point of 
view, this is a public health concern, which encourages 
clinicians working with this age group to be more a tuned 
to this association as well as to provide evidence for 
commissioners to support further development of early 
intervention services in the Maltese islands. 
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